Concepedia

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

Shuyang Yao, Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb, Shannon N. Westin, Aung Naing, Apostolia M. Tsimberidou, David S. Hong,

British Journal of Cancer · 2021 · 36 citations · 22 references

DOIFull text

Open access

Abstract

Concurrently administered ADI-PEG20 and cisplatin had an acceptable safety profile and had shown antitumour activity against metastatic ASS1-deficient solid tumours. Further evaluation of this treatment combination is warranted.

References

22

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

Roger Geiger, Jan C. Rieckmann, Tobias Wolf et al. · Cell · 2016 · 1.6K citations · Full text

Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies

Paolo A. Ascierto, Stefania Scala, Giuseppe Castello et al. · Journal of Clinical Oncology · 2005 · 249 citations

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Ghassan K. Abou‐Alfa, Shukui Qin, Baek‐Yeol Ryoo et al. · Annals of Oncology · 2018 · 243 citations · Full text

, , +8

Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells

Fuming Qiu, Yun‐Ru Chen, Xiyong Liu et al. · Science Signaling · 2014 · 236 citations · Full text

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

Evan S. Glazer, Mauro Piccirillo, Vittorio Albino et al. · Journal of Clinical Oncology · 2010 · 197 citations